News Releases
by Year
2014
Dec. 26, 2014 (PDF/165KB) Corporate
Sumitomo Dainippon Pharma Announces Reorganization of Production Sites
Dec. 25, 2014 (PDF/176KB) R&D
Sumitomo Dainippon Pharma Announces Preliminary Findings from a Phase III Clinical Study (PASTEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia
Dec. 11, 2014 (PDF/171KB) R&D
Investigational Drug Dasotraline Significantly Improved Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in a Placebo-Controlled Study in Adults
Nov. 18, 2014 (PDF/219KB) Products
Sumitomo Dainippon Pharma obtains Approval in Japan for Partial Change of the Approved Indication to "Type 2 Diabetes" for SUREPOST, a Rapid-acting Insulin Secretagogue
Nov. 04, 2014 (PDF/126KB) Corporate
Sumitomo Dainippon Pharma Announces Organizational Realignment, and Changes in Executive Officers and Other Key Positions
Oct. 30, 2014 (PDF/306KB) Finances
Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2015
Oct. 30, 2014 (PDF/287KB) Finances
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2015 [Japanese GAAP] (Unaudited)
Oct. 30, 2014 (PDF/168KB) Corporate
Sumitomo Dainippon Pharma Announces Transfer of a Fixed Asset
Oct. 20, 2014 (PDF/101KB) Products
Announcement of termination of co-promotion of anti-depressant, Paxil CR Tablets
Oct. 01, 2014 (PDF/88KB) Corporate
Sunovion Pharmaceuticals Inc. to Divest Xopenex (levalbuterol HCI) Inhalation Solution (IS) to Akorn, Inc.
Sep. 30, 2014 (PDF/107KB) Licensing
Sumitomo Dainippon Pharma Acquires Patent License from DNAVEC On Clinical-grade iPS Cell Production Technology
Sep. 26, 2014 (PDF/102KB) Licensing
Sumitomo Dainippon Pharma and SanBio Conclude Joint Development and License Agreement for North America With Respect to SB623, a Therapy for Stroke
Aug. 29, 2014 (PDF/113KB) Corporate
Sumitomo Dainippon Pharma Announces Transfer of Certain Fixed Assets
Aug. 21, 2014 (PDF/202KB) Products
Latuda (lurasidone), a New Atypical Antipsychotic Agent for Adults with Schizophrenia, Now Available in the UK, Offers a Combination of Efficacy with Tolerability
Jul. 30, 2014 (PDF/349KB) Finances
Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2015
Jul. 30, 2014 (PDF/151KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2015 (Unaudited)
Jul. 30, 2014 (PDF/58KB) Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts for the Half-Year Ending September 30, 2014
Jul. 23, 2014 (PDF/40KB) Corporate
Sumitomo Dainippon Pharma announces Investment in a New Venture Capital Fund
Jul. 11, 2014 (PDF/168KB) Products
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
Jun. 30, 2014 (PDF/215KB) Corporate
Transfer of Marketing Rights for "Inteban", "Catlep" and "Drenison"
Jun. 19, 2014 (PDF/181KB) Corporate
Sumitomo Dainippon Pharma announces Change of the Company’s English trade name
Jun. 16, 2014 (PDF/127KB) Finances
Dainippon Sumitomo Pharma announces the effects of closure to further patient accrual on its CO.23 study: a phase III global colorectal carcinoma monotherapy trial
Jun. 06, 2014 (PDF/156KB) R&D
Dainippon Sumitomo Pharma announces clinical data of anti-cancer drugs BBI608 and BBI503 were presented at the 2014 ASCO Annual Meeting
May 26, 2014 (PDF/186KB) Licensing
Dainippon Sumitomo Pharma and Daiichi Sankyo Cooperate on Lurasidone, an Atypical Antipsychotic Agent, in Four South American Countries
May 23, 2014 (PDF/115KB) R&D
Dainippon Sumitomo Pharma announces closure to furtherpatient accrual on its CO.23 study: a phase III global colorectal carcinoma monotherapy trial
May 22, 2014 (PDF/174KB) Corporate
Joint Investment into Create Vaccine Company, Ltd.
May 21, 2014 (PDF/183KB) Corporate
Dainippon Sumitomo Pharma Announces Change of the Company’s English trade name and Partial Amendments to Its Articles of Incorporation
May 15, 2014 (PDF/169KB) R&D
Dainippon Sumitomo Pharma announces clinical data of anti-cancer drugs BBI608 and BBI503 will be presented at the 2014 ASCO Annual Meeting
May 08, 2014 (PDF/291KB) Finances
Supplementary Financial Data for the Year Ended March 31, 2014
May 08, 2014 (PDF/693KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2014 [Japanese GAAP] (Unaudited)
May 08, 2014 (PDF/111KB) Corporate
Dainippon Sumitomo Pharma announces Change of Directors
May 08, 2014 (PDF/52KB) Corporate
Dainippon Sumitomo Pharma announces Organizational Realignment and Changes in Executive Officers
May 07, 2014 (PDF/65KB) Corporate
Dainippon Sumitomo Pharma announces personnel changes
Apr. 07, 2014 (PDF/192KB) Products
Once-Daily Aptiom (eslicarbazepine acetate) for the Adjunctive Treatment of Partial-Onset Seizures Now Available in U.S. Pharmacies
Apr. 04, 2014 (PDF/135KB) Finances
Dainippon Sumitomo Pharma Announces Revisions to Its Financial Forecasts for the Year Ended March 31, 2014
Apr. 03, 2014 (PDF/126KB) Products
Dainippon Sumitomo Pharma Announces Health Canada Approval of LATUDA (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Patients with Bipolar Depression
Mar. 31, 2014 (PDF/67KB) Corporate
Dainippon Sumitomo Pharma announces Changes in Executive Officers and Other Key Positions
Mar. 31, 2014 (PDF/131KB) Products
Dainippon Sumitomo Pharma and Takeda Announce the European Marketing Authorization for Latuda (lurasidone) - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
Mar. 25, 2014 (PDF/410KB) Others
Dainippon Sumitomo Pharma Exhibits Heritages of Doshomachi - "The Pharmacy Street" Along with the Company's Century-Old History
Mar. 25, 2014 (PDF/120KB) Products
Dainippon Sumitomo Pharma Announces the Marketing Authorization in Australia for Atypical Antipsychotic Agent Latuda
Mar. 06, 2014 (PDF/53KB) Corporate
Healios and Dainippon Sumitomo Pharma establish a joint venture company for regenerative medicine and cell therapy business
Mar. 04, 2014 (PDF/174KB) Corporate
Dainippon Sumitomo Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Feb. 28, 2014 (PDF/225KB) Corporate
Transfer of Marketing Rights for "Inteban", "Catlep" and "Drenison"
Feb. 19, 2014 (PDF/178KB) Products
Chelsea Therapeutics Obtains US FDA Accelerated Approval on "NORTHERA"
Jan. 31, 2014 (PDF/139KB) Licensing
Dainippon Sumitomo Pharma Deepens Cooperation with Edison Pharmaceuticals for Therapeutic Agents for Mitochondria Disease --- Amends the License Agreement and Concludes a Joint Research Agreement and a Stock Purchase Agreement ---
Jan. 31, 2014 (PDF/228KB) Finances
Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2014
Jan. 31, 2014 (PDF/312KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2014 (Unaudited)
Jan. 27, 2014 (PDF/114KB) R&D
Global Collaboration Forms to Advance Japanese TB Vaccine Technology
Jan. 27, 2014 (PDF/147KB) R&D
Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone - a New Atypical Antipsychotic Medication for Adults with Schizophrenia